All eyes on a hurdle race for a SARS-CoV-2 vaccine

Christian Gaebler () and Michel C. Nussenzweig ()

Nature, 2020, vol. 586, issue 7830, 501-502

Abstract: Leading COVID-19 vaccine candidates have progressed through laboratory tests at record speed. Two early clinical trials suggest that immunization delivers a favourable immune response and safety profile, but questions remain.

Keywords: SARS-CoV-2; Immunology; Vaccines; Medical research (search for similar items in EconPapers)
Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/d41586-020-02926-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:586:y:2020:i:7830:d:10.1038_d41586-020-02926-w

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-020-02926-w

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().